PEG2000-C-DMG

PEG2000-C-DMG

• UNSPSC Description: PEG2000-C-DMG, a pegylated lipid, can be used for the preparation of Onpattro. Onpattro, a hepatically directed investigational RNAi therapeutic agent, harnesses this process to reduce the production of mutant and wild-type transthyretin by targeting the 3′ untranslated region of transthyretin mRNA[1][2].
• Target Antigen: Liposome
• Type: Oligonucleotides
• Related Pathways: Metabolic Enzyme/Protease
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Endocrinology
• Assay Protocol: https://www.medchemexpress.com/peg2000-c-dmg.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: CCCCCCCCCCCCCC(O[C@@H](COC(NCCCOCCOC)=O)COC(CCCCCCCCCCCCC)=O)=O.[45]
• Molecular Weight: 2610.29
• References & Citations: [1]Garber K. Alnylam launches era of RNAi drugs. Nat Biotechnol. 2018;36(9):777-778. |[2]Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11-21.
• Shipping Conditions: Blue Ice
• Clinical Information: No Development Reported